Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University
Bangkok, 10700, Thailand
NCT Number: NCT03246893
Post extubation respiratory failure occur in 30% of extubated patients. More than 50% of them required reintubation. Noninvasive positive pressure ventilation (NIV) had been reported as an effective tool to prevent post extubation respiratory failure. Recently, high flow oxygen nasal cannula (HFNC) had been successfully used to prevent post extubation respiratory failure and prevent reintubation in comparable with NIV among post cardiothoracic surgery and high risk for reintubated patients. There was no information about HFNC versus NIV in prevention of reintubation among severe sepsis or septic shock patients.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Bangkok, 10700, Thailand
Post extubation respiratory failure occur in 30% of extubated patients. More than 50% of them required reintubation. Noninvasive positive pressure ventilation (NIV) had been reported as an effective tool to prevent post extubation respiratory failure. Recently, high flow oxygen nasal cannula (HFNC) had been successfully used to prevent post extubation respiratory failure and prevent reintubation. The results from recent randomized controlled trials, comparing HFNC with NIV for prevent post extubation respiratory failure among post cardiac surgery and high risk patients, showed no significant different in the treatment outcome.comparable with NIV among post cardiothoracic surgery and high risk for reintubated patients.
About 40-85% of severe sepsis/septic shock patients developed acute respiratory failure, required endotracheal intubation. According to the nature of patients population, usually eldery, multiple co-morbid condition and high APACHE II score, sepsis patients were considerred as high risk for reintubation, after extubated. There was no information about HFNC versus NIV in prevention of reintubation among severe sepsis or septic shock patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Noninvasive positive pressure ventilation will apply via a face mask with initial setting as the following:
Inspiratory pressure 6-8 cmH2O Expiratory pressure 3-5 cmH2O FiO2 30-60% Respiratory rate 12-16 per min
Other names: NIV
High flow oxygen nasal cannula will apply to patient via a nasal cannula with initial setting as the following:
Temperature 37 degree celsius Flow 30 liter per min FiO2 40-60%
Other names: HFNC
Time frame: an average of 1 year
Device failure to prevent reintubation, patient discomfort, change to another device within 72 hours after extubation
Time frame: an average of 1 year
Patient develope respiratory failure, requiring reintubation within 72 hours after extubation
Time frame: Upto 28 days
Proportion of dead patients to overall patients
Time frame: an average of 1 year
Proportion of dead patients to overall patients from extubation to discharge date
Mahidol University
Other
Efficacy of High Flow Oxygen Nasal Cannula Versus Noninvasive Positive Pressure Ventilation After Extubation in Sepsis Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06746363
Post Extubation Respiratory Failure
Kaohsiung City, Taiwan
View Trial DetailsNCT06593509
Post Extubation Respiratory Failure
Cairo, Egypt
View Trial DetailsNCT05686850
Post Extubation Respiratory Failure, Respiration Disorders
Brussels, Belgium
View Trial DetailsNCT02361528
Infections, Inflammation
Amiens, France
View Trial Details